Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its upcoming fourth quarter and full year 2024 financial results conference call. The event is scheduled for Monday, March 3, 2025, at 8:00 a.m. Eastern Time.
The company will present business updates and financial performance for the period ending December 31, 2024. Interested parties can join via phone by dialing 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast will be available on the Investors & Media section of www.mersana.com, with a replay accessible for approximately 90 days following the presentation.
Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica specializzata in coniugati farmaco-anticorpo (ADC) per il trattamento del cancro, ha annunciato la sua prossima conference call sui risultati finanziari del quarto trimestre e dell'intero anno 2024. L'evento è programmato per lunedì 3 marzo 2025, alle 8:00 ora orientale.
L'azienda presenterà aggiornamenti aziendali e performance finanziaria per il periodo che termina il 31 dicembre 2024. Le parti interessate possono partecipare telefonicamente componendo il numero 833-255-2826 (nazionale) o 412-317-0689 (internazionale). Sarà disponibile una diretta sul sito della sezione Investitori & Media di www.mersana.com, con una registrazione accessibile per circa 90 giorni dopo la presentazione.
Mersana Therapeutics (NASDAQ: MRSN), una empresa biofarmacéutica en fase clínica especializada en conjugados de anticuerpo-fármaco (ADC) para el tratamiento del cáncer, ha anunciado su próxima conferencia telefónica sobre los resultados financieros del cuarto trimestre y del año completo 2024. El evento está programado para lunes 3 de marzo de 2025, a las 8:00 a.m. hora del Este.
La empresa presentará actualizaciones comerciales y el desempeño financiero para el período que finaliza el 31 de diciembre de 2024. Las partes interesadas pueden unirse por teléfono marcando 833-255-2826 (nacional) o 412-317-0689 (internacional). Se podrá acceder a una transmisión en vivo en la sección de Inversores y Medios de www.mersana.com, con una repetición accesible durante aproximadamente 90 días después de la presentación.
Mersana Therapeutics (NASDAQ: MRSN), 항체-약물 접합체(ADC)를 전문으로 하는 임상 단계의 생명공학 회사가 2024년 4분기 및 연간 재무 결과에 대한 컨퍼런스 콜을 발표했습니다. 이 행사는 2025년 3월 3일 월요일 오전 8시 동부 표준시에 예정되어 있습니다.
회사는 2024년 12월 31일로 종료되는 기간에 대한 비즈니스 업데이트 및 재무 성과를 발표할 것입니다. 관심 있는 분들은 833-255-2826 (국내) 또는 412-317-0689 (국제)로 전화하여 참여할 수 있습니다. www.mersana.com의 투자자 및 미디어 섹션에서 실시간 웹캐스트를 이용할 수 있으며, 발표 후 약 90일 동안 다시 볼 수 있습니다.
Mersana Therapeutics (NASDAQ: MRSN), une entreprise biopharmaceutique en phase clinique spécialisée dans les conjugués anticorps-médicament (ADC) pour le traitement du cancer, a annoncé sa prochaine conférence téléphonique sur les résultats financiers du quatrième trimestre et de l'année complète 2024. L'événement est prévu pour lundi 3 mars 2025, à 8h00, heure de l'Est.
L'entreprise présentera des mises à jour commerciales et des performances financières pour la période se terminant le 31 décembre 2024. Les parties intéressées peuvent se joindre par téléphone en composant le 833-255-2826 (national) ou le 412-317-0689 (international). Un webinaire en direct sera disponible dans la section Investisseurs & Médias de www.mersana.com, avec une rediffusion accessible pendant environ 90 jours suivant la présentation.
Mersana Therapeutics (NASDAQ: MRSN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Antikörper-Wirkstoff-Konjugate (ADCs) zur Krebsbehandlung spezialisiert hat, hat seine bevorstehende Telefonkonferenz zu den finanziellen Ergebnissen des vierten Quartals und des gesamten Jahres 2024 angekündigt. Die Veranstaltung ist für Montag, den 3. März 2025, um 8:00 Uhr Eastern Time angesetzt.
Das Unternehmen wird Geschäftsupdates und die finanzielle Leistung für den Zeitraum bis zum 31. Dezember 2024 präsentieren. Interessierte Parteien können telefonisch unter 833-255-2826 (national) oder 412-317-0689 (international) teilnehmen. Ein Live-Webcast wird im Bereich Investoren & Medien auf www.mersana.com verfügbar sein, mit einer Wiederholung, die etwa 90 Tage nach der Präsentation zugänglich ist.
- None.
- None.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
When will Mersana Therapeutics (MRSN) report Q4 and full-year 2024 earnings?
How can investors access Mersana's (MRSN) Q4 2024 earnings call?
How long will Mersana's (MRSN) Q4 2024 earnings webcast be available for replay?
What is Mersana Therapeutics' (MRSN) primary focus in drug development?
